Narrow search
Showing 1 - 10 of 160
Cover Image
Cost-utility analysis of total knee arthroplasty for osteoarthritis in a regional medical center in China
Gui, Qi; Zhang, Xinghuo; Liu, Liang; Zhao, Feng; Cheng, … - In: Health Economics Review 9 (2019) 15, pp. 1-8
its effectiveness of the treatment. The total expense was the cost of patient hospitalization. The cost per QALY was … calculated. The cost-benefit ratio (CBR) was expressed as a ratio of each QALY's expenditure to per capita gross domestic product … age and sex, a total of ?2487.74 QALYs and ?3237.37/QALY were gained, 10% less than the regional GDP per capita. The cost …
Persistent link: https://www.econbiz.de/10014489948
Cover Image
Cost-utility analysis of total knee arthroplasty for osteoarthritis in a regional medical center in China
Gui, Qi; Zhang, Xinghuo; Liu, Liang; Zhao, Feng; Cheng, … - In: Health economics review 9 (2019) 15, pp. 1-8
its effectiveness of the treatment. The total expense was the cost of patient hospitalization. The cost per QALY was … calculated. The cost-benefit ratio (CBR) was expressed as a ratio of each QALY’s expenditure to per capita gross domestic product … age and sex, a total of ?2487.74 QALYs and ?3237.37/QALY were gained, 10% less than the regional GDP per capita. The cost …
Persistent link: https://www.econbiz.de/10012033167
Cover Image
Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia
Nallamothu, Brahmajee K.; Fendrick, A. Mark; Omenn, … - In: PharmacoEconomics 20 (2002) 7, pp. 429-442
Homocyst(e)ine, a sulphur-containing amino acid, is an intermediate formed during the metabolism of the essential amino acid methionine. Biological and epidemiological evidence suggest that elevated plasma levels of homocyst(e)ine are a risk factor for atherosclerosis and coronary heart disease...
Persistent link: https://www.econbiz.de/10005243072
Cover Image
Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium
Neymark, Niels; Gorlia, Thierry; Adriaenssen, Ines; … - In: PharmacoEconomics 20 (2002) 7, pp. 485-497
Objective: To assess the economic impact of two polychemotherapy regimens for patients with advanced ovarian cancer from the perspective of the Belgian health insurance and financing system. Design: An economic evaluation was integrated in an intergroup randomised controlled trial (EORTC 55931)...
Persistent link: https://www.econbiz.de/10005243077
Cover Image
Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion
Duda, Stephan H.; Tepe, Gunnar; Bala, Mohan; Luz, Oliver; … - In: PharmacoEconomics 20 (2002) 3, pp. 203-213
Background and objective: Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6...
Persistent link: https://www.econbiz.de/10005243085
Cover Image
Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance
Kuti, Joseph L.; Capitano, Blair; Nicolau, David P. - In: PharmacoEconomics 20 (2002) 8, pp. 513-528
Community-acquired pneumonia (CAP) infects upwards of four million people in the US each year, of which 20% require subsequent hospitalisation. Consequently, it is a large contributor to excessive healthcare resource consumption and cost. Since the aetiology of CAP is not identified in a...
Persistent link: https://www.econbiz.de/10005243094
Cover Image
An Epidemiological Approach to Assess the Economic Burden of NSAID-Induced Gastrointestinal Events in The Netherlands
Herings, Ronald M.C.; Klungel, Olaf H. - In: PharmacoEconomics 19 (2001) 6, pp. 655-665
Objective: To use the population attributable risk (PAR) to estimate the treatment costs resulting from nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) morbidity. Design: Two case-control studies with the following outcomes: (i) the start of therapy with...
Persistent link: https://www.econbiz.de/10005243100
Cover Image
Clinical and Economic Factors Important to Anaesthetic Choice for Day-Case Surgery
Eger, Edmond I.; White, Paul F.; Bogetz, Martin S. - In: PharmacoEconomics 17 (2000) 3, pp. 245-262
Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery,...
Persistent link: https://www.econbiz.de/10005243102
Cover Image
Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine
Brett Hauber, A.; Gnanasakthy, Ari; Snyder, Edward H.; … - In: PharmacoEconomics 17 (2000) 4, pp. 351-360
Objective: To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. Design and setting:...
Persistent link: https://www.econbiz.de/10005243104
Cover Image
The Cost of Urinary Incontinence in Italian Women: A Cross-Sectional Study
Tediosi, Fabrizio; Parazzini, Fabio; Bortolotti, Angela; … - In: PharmacoEconomics 17 (2000) 1, pp. 71-76
Objective: To offer cost estimates of urinary incontinence (UI) in the general population based on prospectively collected data. Design: We analysed individual costs in a sample of women with UI who were identified in the framework of a cross-sectional study on the prevalence of UI in women aged...
Persistent link: https://www.econbiz.de/10005243106